Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition and demonstrated high selectivity over other PDE families.
Scientists at Institució Catalana de Recerca i Estudis Avançats and Universitat de Barcelona have identified three-prime repair exonuclease 2 (TREX2) inhibitors reported to be useful for the treatment of psoriasis, atopic dermatitis and ichthyosis.
Blood dendritic cell antigen 2 (BDCA2) is expressed in plasmacytoid dendritic cells. These cells’ overproduction of type I interferon is closely linked to the pathogenesis of systemic lupus erythematosus and other autoimmune diseases.
Protagonist Therapeutics Inc. has selected PN-881, an oral peptide interleukin-17 (IL-17) antagonist, as a development candidate for the treatment of immune-mediated skin diseases.
South Korean researchers developed a novel quantum dot and parallel-stacked organic light-emitting diode (QD-PSOLED)-based wearable patch capable of being “freely tunable” in real-time, and described as a flexible and commercial-level technology with wide applications for health care wearables.
Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the way to accelerate clinical development in psoriasis and other autoimmune diseases.
Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the way to accelerate clinical development in psoriasis and other autoimmune diseases.
Artelo Biosciences Inc. has presented data on its fatty acid-binding protein 5 (FABP5) inhibitor ART-26.12 from testing of its efficacy in preclinical models of psoriasis.
